Myoglobin Articles & Analysis

8 news found

CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference

Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. ...

Apr. 19, 2022

ByCytoSorbents Corporation

CytoSorbents To Expand Direct Sales of CytoSorb to the United Kingdom, the Sixth Largest Medical Device Market in the World

Apr. 14, 2022

ByCytoSorbents Corporation

CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program

Apr. 7, 2022

ByCytoSorbents Corporation

CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

Dec. 21, 2021

ByCytoSorbents Corporation

CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

Dec. 20, 2021

ByCytoSorbents Corporation

First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

Oct. 14, 2021

ByCytoSorbents Corporation

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

Oct. 12, 2021

ByCytoSorbents Corporation

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

Oct. 7, 2021

ByCytoSorbents Corporation

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you